AI in Oncology: Predicting Adverse Drug Reactions in Hematologic Malignancies
Christos Evangelou, PhDPrint | June 19, 2025

The advent of artificial intelligence technologies such as machine learning, deep learning, and natural language processing has opened new avenues for predicting adverse drug reactions with greater accuracy and efficiency.

Advertisement
Advertisement

Advertisement
Editorial Board

Podcasts

Rahul Banerjee, MD, FACPThe HemOnc Pulse | June 20, 2025
Can tech bridge the cancer care gap? Dr. Banerjee and Dr. Longmire explore solutions for drug accessibility.
Listen Now
Rahul Banerjee, MD, FACPAggressive B-Cell Lymphoma | June 9, 2025
Experts explore CAR T therapy challenges and the future of lymphoma care beyond CD19-targeted treatments.
Rahul Banerjee, MD, FACPAcute Myeloid Leukemia | May 23, 2025
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
Rahul Banerjee, MD, FACPMyelodysplastic Syndromes | June 5, 2025
At The HemOnc Pulse Live!, experts debate key controversies in MDS care, from frontline therapy to emerging treatments.
Rahul Banerjee, MD, FACPMyeloma | May 5, 2025
Gurbakhash Kaur, MD joins the host of The HemOnc Pulse Live! for a comprehensive discussion about the RedirecT-1 trial.
Saad Z. Usmani, MD, MBA, FACPThe HemOnc Pulse | November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Sangeetha Venugopal, MDThe HemOnc Pulse | November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Naval Daver, MDThe HemOnc Pulse | October 22, 2024
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.

Video Insights

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia

Trending on MashupMD

Network Websites